BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)

BTIG analyst Justin Zelin reiterated a Buy rating and $125.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst comments "Today, Viking Therapeutics announced the initiation of their Two Phase 3 Obesity VANQUISH studies with VK2735. We are encouraged by Viking's execution and progress across their obesity franchise and continue to see tremendous value in the company's potentially best-in-class portfolio of obesity and metabolic disease programs. Both studies are randomized, double-blind, pbo-controlled, multi-center trials assessing QW SC VK2735 for 78-weeks. VANQUISH-1 will enroll ~4500 obese adults or overweight with a comorbid condition, VANQUISH-2 will enroll ~1100 T2D patients who are obese or overweight. Patients will be randomized to one of four weekly treatment soaking arms: 7.5, 12.5, 17.5mg, or pbo. The primary endpoint is % weight loss from baseline. Both studies will include an open-label extension (OLE) for patients to continue receiving treatment following completion of the studies. We also look forward to oral VK2735 data from the VENTURE study in 2H25, where we expect high investor interest. We recently hosted Viking's CEO Brian Lian during our Obesity Health Forum this month (see here), please contact us or BTIG Corporate Access to register for replay access. We reiterate our Buy rating and $125 PT."

For an analyst ratings summary and ratings history on Viking Therapeutic click here. For more ratings news on Viking Therapeutic click here.

Shares of Viking Therapeutic closed at $26.95 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Aeva Technologies files mixed shelf offering registration
• Meta plans 'Hatch' AI agent priced at up to $200/month - The Information